SynKIR-310 for Relapsed/Refractory B-NHL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
SynKIR-310 for Relapsed/Refractory B-NHL	B-cell neoplasm, Blood Protein Disorders, Digestive System Diseases, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, T-cell/histiocyte rich large B cell lymphoma, Waldenstrom macroglobulinemia, aggressive B-cell non-Hodgkin lymphoma, cardiovascular disorder, diffuse large B-cell lymphoma, digestive system disorder, follicular lymphoma, hematologic disorder, hemorrhagic disease, high grade B-cell lymphoma, histiocytosis, hypertrophic pyloric stenosis, immune system disorder, immunoproliferative disorder, indolent B-cell non-Hodgkin lymphoma, interdigitating dendritic cell sarcoma, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, pyloric stenosis, stomach disorder, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-04-14		NCT06544265

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Verismo Therapeutics	3

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	United States	47
Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute	Denver	United States	1
Rutgers Cancer Institute	New Brunswick	United States	2
The University of Kansas Cancer Center	Fairway	United States	7
Winship Cancer Institute of Emory University	Atlanta	United States	45